# Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma

> **NCT00338494** · PHASE1 · COMPLETED · sponsor: **Yale University** · enrollment: 16 (actual)

## Conditions studied

- B-Cell Lymphoma

## Interventions

- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT00338494
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2010-03
- **Final completion:** 2011-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2015-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338494, "Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00338494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*